Trials / Recruiting
RecruitingNCT06885957
Monoclonal Antibody-Based Therapies for AQP4-Positive NMOSD
A Registry Study on Monoclonal Antibody-Based Therapies for Aquaporin-4 Antibody-Positive Neuromyelitis Optica Spectrum Disorders
- Status
- Recruiting
- Phase
- —
- Study type
- Observational
- Enrollment
- 200 (estimated)
- Sponsor
- Tongji Hospital · Academic / Other
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
The primary objective of this registry study is to evaluate the therapeutic efficacy and safety profiles of distinct monoclonal antibody-based therapies for aquaporin-4 immunoglobulin G-seropositive neuromyelitis optica spectrum disorders within the Chinese population under real-world clinical conditions. Secondary objectives include quantitative assessment of longitudinal neuroimaging biomarker variations and immunological profile alterations in longitudinal biological specimens pre- and post-therapeutic intervention.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Mab Therapy | Whether receive mab therapy or not. |
Timeline
- Start date
- 2025-07-01
- Primary completion
- 2027-06-30
- Completion
- 2027-12-31
- First posted
- 2025-03-20
- Last updated
- 2025-09-08
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT06885957. Inclusion in this directory is not an endorsement.